Physician profile
Glenn D Garbutt
NPI 1063513737
$4,475.43
in general payments reported to CMS, 2019-2025
18 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $224 · 2021: $786 · 2022: $1,006 · 2023: $811 · 2024: $771 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.33 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $881.70 | 2019-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $815.84 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $570.23 | 2019-2025 | Krystexxa, Parsabiv, Tavneos |
| Vifor Pharma, INC. | $423.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $298.89 | 2021-2023 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $250.69 | 2019-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $196.70 | 2022-2024 | Tarpeyo |
| Horizon Therapeutics Plc | $176.98 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $165.53 | 2019-2025 | Jynarque |
| Lilly USA, LLC | $158.77 | 2023-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $156.65 | 2023-2025 | Ozempic |
| Mallinckrodt Hospital Products INC. | $147.96 | 2021 | |
| Aurinia Pharma U.S., INC. | $72.43 | 2023-2025 | Lupkynis |
| Ardelyx, INC. | $53.28 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $48.07 | 2024-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.72 | 2024 | Jardiance |
| Abbott Laboratories | $19.73 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $17.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Garbutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.